Covered recipient · General Payments record
SAIWARD WHITENER GLENN
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$1,712.38
- Reported across 114 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $269.86 | 15 |
| Education | $64.54 | 2 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $158.39 | 10 |
| Acerta Pharma LLC | $81.21 | 1 |
| ABBVIE INC. | $33.00 | 2 |
| DEXCOM, INC. | $30.27 | 2 |
| PFIZER INC. | $17.11 | 1 |
| GlaxoSmithKline, LLC. | $14.42 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $13.56 | 03/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103804094 | CMS |
| ABBVIE INC. | $19.44 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103804096 | CMS |
| AstraZeneca Pharmaceuticals LP | $81.21 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105256382 | CMS |
| Dexcom, Inc. | $15.35 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153333437 | CMS |
| Dexcom, Inc. | $14.92 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153333439 | CMS |
| GlaxoSmithKline, LLC. | $14.42 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116490516 | CMS |
| Novo Nordisk Inc | $9.96 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097264536 | CMS |
| Novo Nordisk Inc | $11.84 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096892067 | CMS |
| Novo Nordisk Inc | $32.27 | 02/28/2024 | Education | Undisputed | 01/23/2026 | 1097013865 | CMS |
| Novo Nordisk Inc | $32.27 | 02/28/2024 | Education | Undisputed | 01/23/2026 | 1097018717 | CMS |
| Novo Nordisk Inc | $10.71 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096911267 | CMS |
| Novo Nordisk Inc | $11.46 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096782465 | CMS |
| Novo Nordisk Inc | $13.82 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097809399 | CMS |
| Novo Nordisk Inc | $11.23 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097353240 | CMS |
| Novo Nordisk Inc | $11.97 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097414199 | CMS |
| Novo Nordisk Inc | $12.86 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097132605 | CMS |
| PFIZER INC. | $17.11 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131725974 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.